With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

In the next couple months, Dermavant CEO Todd Zavodnick says he’ll sprint to the FDA with tapinarof, the company’s “cosmetically elegant” vanishing cream to treat psoriasis. But before that, he has more Phase III data to share.

Around 20% of moderate to severe plaque psoriasis patients given tapinarof in two...

Click to view original post